Worg is a clinical stage biopharmaceutical company developing new treatments for allergy and other diseases with high unmet medical needs and considerable commercial potential.

Headquartered in Hangzhou at the heart of one of China's biotech hubs, Worg was founded in 2018 and led by an executive team from China, the United States and Europe who have extensive experience in life science executive, pharmaceutical development, clinical trials, regulatory affairs and commercialization.

Worg accelerates product development based on the team's strong international drug development experience and deliver successful registration and commercialization globally. Worg plans to build the pipeline of allergy and other therapeutical indications through internal development and external partnering with flexible options.